Short Interest in enVVeno Medical Corporation (NASDAQ:NVNO) Rises By 19.4%

enVVeno Medical Corporation (NASDAQ:NVNO - Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 469,500 shares, an increase of 19.4% from the April 30th total of 393,100 shares. Based on an average daily trading volume, of 86,200 shares, the short-interest ratio is currently 5.4 days. Approximately 2.7% of the company's stock are sold short.

Institutional Investors Weigh In On enVVeno Medical

Several institutional investors have recently bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new position in enVVeno Medical during the 4th quarter worth $39,000. Jane Street Group LLC purchased a new position in enVVeno Medical during the fourth quarter worth about $56,000. National Bank of Canada FI purchased a new stake in enVVeno Medical in the 4th quarter valued at about $60,000. XTX Topco Ltd bought a new position in shares of enVVeno Medical during the 1st quarter worth approximately $80,000. Finally, Virtu Financial LLC bought a new position in shares of enVVeno Medical in the fourth quarter valued at approximately $86,000. Institutional investors own 34.71% of the company's stock.

enVVeno Medical Price Performance

Shares of NASDAQ NVNO traded up $0.21 during mid-day trading on Wednesday, reaching $3.68. 84,599 shares of the company's stock traded hands, compared to its average volume of 113,564. The business has a 50-day simple moving average of $3.03 and a 200 day simple moving average of $3.10. The stock has a market cap of $64.53 million, a P/E ratio of -2.85 and a beta of 0.80. enVVeno Medical has a 1-year low of $2.03 and a 1-year high of $6.48.

enVVeno Medical (NASDAQ:NVNO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.22) EPS for the quarter. Equities research analysts anticipate that enVVeno Medical will post -1.32 earnings per share for the current fiscal year.

About enVVeno Medical

enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.